Skip to main content
. 2015 Oct 26;6(42):44466–44479. doi: 10.18632/oncotarget.6298

Figure 2. MiR-181c directly targets the core components of the Hippo signaling pathway.

Figure 2

A. Predicted miR-181c target sequence in 3′UTRs of MST1, LATS2, MOB1 and SAV1. B. Western blots of MST1, LATS2, MOB1 and SAV1 expression. α-Tubulin served as the loading control. C. Luciferase assay of cells transfected with pGL3-MST1-3′UTR, pGL3-LATS2-3′UTR, pGL3-MOB1-3′UTR or pGL3-SAV1-3′UTR reporter with miR-181c mimic, antagomiR-181c, mimic control or antagomiR control. D. MiRNP IP assay showing the association between miR-181c and MST1, LATS2, MOB1 and SAV1 transcripts, but not YAP or TAZ in PANC-1 cells. GAPDH served as the negative control. Error bars represent the mean ± s.d. of three independent experiments. *P < 0.05.